Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2688418 | 1.00 | CYP2C9 (0.46) | CYP2C9TSHRCYP2C19TDP1CHRM2 | |
| SCHEMBL2688419 | 1.00 | CYP2C9 (0.46) | CYP2C9TSHRCYP2C19TDP1CHRM2 | |
| Hydrochloric Acid SCHEMBL7202039 | 0.98 | TSHR (0.44) | CYP2C9TSHRCYP2C19TDP1CHRM2 | |
| Hydrochloric Acid SCHEMBL2689316 | 0.98 | TSHR (0.44) | CYP2C9TSHRCYP2C19TDP1CHRM2 | |
| Hydrochloric Acid SCHEMBL2689317 | 0.98 | TSHR (0.44) | CYP2C9TSHRCYP2C19TDP1CHRM2 | |
| Hydrochloric Acid SCHEMBL2689322 | 0.98 | TSHR (0.44) | CYP2C9TSHRCYP2C19TDP1CHRM2 | |
| SCHEMBL2691455 | 0.89 | CYP2C9 (0.43) | CYP2C9TSHRCYP2C19TDP1CHRM2 | |
| SCHEMBL2691460 | 0.89 | CYP2C9 (0.43) | CYP2C9TSHRCYP2C19TDP1CHRM2 | |
| SCHEMBL2691453 | 0.89 | CYP2C9 (0.43) | CYP2C9TSHRCYP2C19TDP1CHRM2 | |
| Hydrochloric Acid SCHEMBL2688904 | 0.87 | TSHR (0.41) | CYP2C9TSHRCYP2C19TDP1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168657-B2 | administering a solenopsin derivative such as 2-methyl-6-(2-phenylethyl)piperidine or other piperidine derivatives to treat a tumor or cancer in a patient | BOWEN J PHILLIP (US) | 2012-05-01 | — | — | US | disclosed |
| US-20050038071-A1 | Solenopsin a, b and analogs and as novel angiogenesis inhibitors | BOWEN J PHILLIP (US) | 2005-02-17 | — | — | US | disclosed |
| US-6369078-B1 | Solenopsin derivatives and analogues as fire ant suppressants | BOWEN J PHILLIP (US) | 2002-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038071-A1 | Solenopsin a, b and analogs and as novel angiogenesis inhibitors | VEGFA, TEK, FLT1 | CYP2C9 3945/4885TSHR 4702/4885CYP2C19 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.